终末期肝病患者肠屏障功能的变化及营养干预研究进展

doi:10.3969/j.issn.1006-7795.2018.05.026

首都医科大学学报 ›› 2018, Vol. 39 ›› Issue (5): 759-764.doi: 10.3969/j.issn.1006-7795.2018.05.026

终末期肝病患者肠屏障功能的变化及营养干预研究进展

毕研贞, 陈煜

首都医科大学附属北京佑安医院疑难肝病及人工肝中心肝衰竭及人工肝治疗研究北京市重点实验室, 北京 100069

收稿日期:2018-08-28 出版日期:2018-09-21 发布日期:2018-10-20
通讯作者: 陈煜 E-mail:chybeyond@163.com
基金资助:
国家科技重大专项（2017ZX10203201-005，2017ZX10202203-006-001，2017ZX10302201-004-002，2012ZX10002004-006，2017ZX10201201），国家重点研发计划（2017YFA0103000），北京市医院管理局"登峰"人才培养计划基金资助项目（DFL20151601），北京市医院管理局临床医学发展专项经费资助（ZYLX201806），北京市科技计划课题（Z171100002217070）。

Effect of nutritional intervention on intestinal barrier in patients with end-stage liver disease

Bi Yanzhen, Chen Yu

Artificial Liver Treatment & Training Center, Beijing Youan Hospital, Capital Medical University, Beijing Key Laboratory of Liver Failure and Artificial Liver Treatment and Research, Beijing 100069, China

Received:2018-08-28 Online:2018-09-21 Published:2018-10-20
Supported by:
This study was supported by National Science and Technology Key Project (2017ZX10203201-005, 2017ZX10202203-006-001, 2017ZX10302201-004-002, 2012ZX10002004-006, 2017ZX10201201), National Key R&D Program of China (2017YFA0103000), "Beijing Muncipal Administration of Hospitals" Ascent Plan (DFL20151601), Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201806).

摘要/Abstract

摘要： 肠道除具有消化、吸收、分泌功能外，还起到重要的屏障功能。终末期肝病患者大多出现肠屏障功能受损，导致细菌移位和内毒素血症，后者又进一步加重肝脏损伤。营养不良亦是终末期肝病患者的常见合并症，机体营养状态的好坏直接影响肝病的发生、发展和预后。通过营养干预来维护肠屏障的功能，对终末期肝病的治疗有重要的临床意义，本文就近年来有关此问题的研究作一综述。

关键词: 终末期肝病, 营养, 肠屏障

Abstract: The intestine plays an important barrier function, apart from the functions of digestion, absorption and secretion. Most patients with end-stage liver disease have impaired functions of intestinal barrier, leading to bacterial translocation and endotoxemia, which further aggravates liver injury. Malnutrition is also a common complication of patients with end-stage liver disease. The nutritional status of patients directly affects the occurrence, development and prognosis of liver disease. Maintaining the function of the intestinal barrier through nutritional intervention has important clinical significance for the treatment of end-stage liver disease. This review is intended to summarize the latest progresses in this area.

Key words: end-stage liver disease, nutrition, intestinal barrier

中图分类号:

R575

毕研贞, 陈煜. 终末期肝病患者肠屏障功能的变化及营养干预研究进展[J]. 首都医科大学学报, 2018, 39(5): 759-764.

Bi Yanzhen, Chen Yu. Effect of nutritional intervention on intestinal barrier in patients with end-stage liver disease[J]. Journal of Capital Medical University, 2018, 39(5): 759-764.

参考文献

[1] Schmid-Schönbein G W, Chang M. The autodigestion hypothesis for shock and multi-organ failure[J]. Ann Biomed Eng, 2014, 42(2):405-414.
[2] Giannelli V, Di Gregorio V, Iebba V, et al. Microbiota and the gut-liver axis:bacterial translocation, inflammation and infection in cirrhosis[J]. World J Gastroenterol, 2014, 20(45):16795-16810.
[3] Maharshi S, Sharma B C, Srivastava S. Malnutrition in cirrhosis increases morbidity and mortality[J]. J Gastroenterol Hepatol, 2015, 30(10):1507-1513.
[4] Beaufrère A M, Neveux N, Patureau Mirand P, et al. Long-term intermittent glutamine supplementation repairs intestinal damage (structure and functional mass) with advanced age:assessment with plasma citrulline in a rodent model[J]. J NutrHealth Aging, 2014, 18(9):814-819.
[5] Reiberger T, Ferlitsch A, Payer B A, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis[J]. J Hepatol, 2013, 58(5):911-921.
[6] Turner J R. Intestinal mucosal barrier function in health and disease[J]. Nat Rev, 2009, 9(11):799-809.
[7] Woodhouse C A, Patel V C, Singanayagam A, et al. Review article:the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease[J]. Aliment Pharmacol Ther, 2018, 47(2):192-202.
[8] Traykova D, Schneider B, Chojkier M, et al. Blood microbiome quantity and the hyperdynamic circulation in decompensated cirrhotic patients[J]. PLoS One, 2017, 12(2):e0169310.
[9] Assimakopoulos S F, Tsamandas A C, Tsiaoussis G I, et al. Intestinal mucosal proliferation, apoptosis and oxidative stress in patients with liver cirrhosis[J]. Ann Hepatol, 2013, 12(2):301-317.
[10] Assimakopoulos S F, Tsamandas A C, Tsiaoussis G I, et al. Altered intestinal tight junctions' expression in patients with liver cirrhosis:a pathogenetic mechanism of intestinal hyperpermeability[J].Eur J Clin Invest, 2012, 42(4):439-446.
[11] Ye D, Guo S, Al-Sadi R, et al. MicroRNA regulation of intestinal epithelial tight junction permeability[J]. Gastroenterology, 2011, 141(4):1323-1333.
[12] Assimakopoulos S F,Charonis A S. Uncovering the molecular events associated with increased intestinal permeability in liver cirrhosis:the pivotal role of enterocyte tight junctions and future perspectives[J]. J Hepatol, 2013, 59(5):1144-1146.
[13] Schierwagen R, Alvarez-Silva C, Madsen M S A, et al. Circulating microbiome in blood of different circulatory compartments[J]. Gut, 2018, pii:gutjnl-2018-316227.
[14] Elamin E E, Masclee A A, Dekker J, et al. Ethanol metabolism and its effects on the intestinal epithelial barrier[J]. Nutr Rev, 2013, 71(7):483-499.
[15] Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction:distinctive features and clinical relevance[J].J Hepatol, 2014, 61(6):1385-1396.
[16] Muñoz L, Albillos A, Nieto M, et al.Mesenteric Th1 polarization and monocyte TNF-alpha production:first steps to systemic inflammation in rats with cirrhosis[J]. Hepatology, 2005, 42(2):411-419.
[17] Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis[J]. Nature, 2014, 513(7516):59-64.
[18] Ponziani F R, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease[J].Hepatology, 2018. doi:10.1002/hep.30036.
[19] Limin S, Masayuki F, Nanthakumar T, et al. Toll -like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria[J]. Gastroenterology, 2008, 135(2):529-538.
[20] Suzuki K, Meek B, Doi Y, et al. Aberrant expansion of segamented filamentous bacteria in IgA-deficient gut[J]. Proc Natl Acad Sci USA, 2004, 101(7):1981-1986.
[21] Tang Q J, Wang L M, Tao K Z, et al. Expression of polymeric immunoglobulin receptor mRNA and protein in human paneth cells:paneth cells participate in acquired immunity[J]. Am J Gastroenterol, 2006, 101(7):1625-1632.
[22] Chen Y, Guo J, Qian G, et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality[J]. J Gastroenterol Hepatol, 2015, 30(9):1429-1437.
[23] Mehta A K, Lyon G M 3rd. Infectious diseases in end-stage liver disease patients[J]. Crit Care Nurs Clin North Am, 2010, 22(3):291-307.
[24] Yu L, Yan H, Liu Q, et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents[J]. Hepatology, 2010, 52(4):1322-1333.
[25] Zhang H, Yu L, Yang W, et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats[J]. J Hepatol, 2012, 57(4):803-812.
[26] Dapito D H, Mencin A, Gwak G Y, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4[J]. Cancer Cell, 2012, 21(4):504-516.
[27] Tao X, Wang N, Qin W. Gut microbiota and hepatocellular carcinoma[J]. Gastrointest Tumors, 2015, 2(1):33-40.
[28] Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for earlyhepatocellular carcinoma[J]. Gut, 2018, pii:gutjnl-2017-315084.
[29] Sanduzzi Z M, Rocco A, Compare D, et al. The gut microbiota:a new potentiall driving force in liver cirrhosis and hepatocellular carcinoma[J]. United European Gastroenterol J, 2017, 5(7):944-953.
[30] Aguirre Valadez J M, Rivera-Espinosa L, Méndez-Guerrero O, et al. Intestinal permeability in a patient with liver cirrhosis[J]. Ther Clin Risk Manag, 2016, 12:1729-1748.
[31] Adams D H, Eksteen B, Curbishley S M. Immunology of the gut andliver:a love/hate relationship[J]. Gut, 2008, 57(6):838-848.
[32] Dodd D, Spitzer M H, Van T W, et al. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites[J]. Nature, 2017, 551(7682):648-652.
[33] Seidel D V, Azcárate-Peril M A, Chapkin R S, et al. Shaping functional gut microbiota using dietary bioactives to reduce colon cancer risk[J]. Semin Cancer Biol, 2017, 46:191-204.
[34] Lyu M, Wang Y F, Fan G W, et al. Balancing herbal medicine and functional food for prevention and treatment of cardiometabolic diseases through modulating gut microbiota[J]. Front Microbiol, 2017, 8:2146.
[35] Desai M S, Seekatz A M, Koropatkin N M, et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibiliy[J]. Cell, 2016, 167(5):1339-1353.e21.
[36] Sonnenburg E D, Smits S A, Tikhonov M, et al. Diet-induced extinctions in the gut microbiota compound over generations[J]. Nature, 2016, 529(7585):212-215.
[37] Parker E A, Roy T, D'Adamo C R, et al. Probiotics and gastrointestinal conditions:An overview of evidence from the cochrane collaboration[J]. Nutrition, 2018, 45:125-134.e11.
[38] Merli M, Iebba V, Giusto M. What is new about diet in hepatic encephalopathy[J]. Metab Brain Dis, 2016, 31(6):1289-1294.
[39] Marlicz W, Wunsch E, Mydlowska M, et al. The effect of short term treatment withprobiotic VSL#3 on various clinical and biochemical parameters in patients with livercirrhosis[J]. J Physiol Pharmacol, 2016, 67(6):867-877.
[40] Zhernakova A, Kurilshikov A, Bonder M J, et al.Population-based metage omics analysis reveals markers for gut microbiome composition and diversit[J]. Science, 2016, 352(6285):565-569.
[41] Falony G, Joossens M, Vieira-Silva S, et al. Population-level analysis of gut microbiome variation[J]. Science,2016, 352(6285):560-564.
[42] Leitão-Gonçalves R, Carvalho-Santos Z, Francisco A P,et al. Commensal bacteria and essential amino acids control food choice behavior and reproduction[J]. PLoS Biol, 2017, 15(4):e2000862.
[43] Singh R K, Chang H W, Yan D, et al. Influence of diet on the gut microbiome and implications for human health[J]. J Transl Med, 2017, 15(1):73.

终末期肝病患者肠屏障功能的变化及营养干预研究进展

Effect of nutritional intervention on intestinal barrier in patients with end-stage liver disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙丛丛, 吴涵, 周丹娜, 姜玮, 王雯, 杨春林, 马辛, 任艳萍. 脑源性神经营养因子对经颅磁刺激治疗难治性抑郁症的疗效预测作用[J]. 首都医科大学学报, 2022, 43(2): 227-232.
[2]	高明, 周营利, 朱研, 秦君平, 黄惠斌, 任昱, 谈莉, 周华, 许媛. 重症患者急性期能量平衡对住院期间死亡的影响[J]. 首都医科大学学报, 2021, 42(6): 931-935.
[3]	于恺英, 王晓琳, 石汉平. 肿瘤营养治疗的发展与进步[J]. 首都医科大学学报, 2021, 42(3): 499-502.
[4]	马兰芳, 薛怡蓉. 面向慢性病人群的智能膳食评估系统[J]. 首都医科大学学报, 2021, 42(2): 262-268.
[5]	杨楠, 丁锚, 黄语悠, 房亚兰, 师文娟, 赵咏梅. 一氧化氮在大鼠短暂性局灶性脑缺血损伤中对神经生长因子和脑源性神经营养因子表达的影响[J]. 首都医科大学学报, 2020, 41(6): 908-913.
[6]	王欣, 张俊璇, 高健, 石汉平. 免疫营养改善肿瘤患者预后[J]. 首都医科大学学报, 2020, 41(6): 1019-1024.
[7]	刘月. 集束化干预在急性胰腺炎肠内营养患者中的应用效果观察[J]. 首都医科大学学报, 2020, 41(3): 488-491.
[8]	杨翠翠, 包训杰, 张丽, 李雅莉, 李林, 张兰. 山茱萸环烯醚萜苷对APP/PS1/Tau三转基因小鼠脑内病理变化的影响[J]. 首都医科大学学报, 2019, 40(4): 588-595.
[9]	吴慧博, 赵海英, 朱圣韬, 吴咏冬, 张澍田. 不同营养素对活动期溃疡性结肠炎患者肠道生物屏障的影响[J]. 首都医科大学学报, 2019, 40(4): 635-639.
[10]	石汉平, 贾平平. 我国肿瘤营养事业的发展与挑战[J]. 首都医科大学学报, 2019, 40(2): 159-162.
[11]	房亚兰, 黄语悠, 赵咏梅, 李锦程, 段云霞, 高利, 罗玉敏. 大黄酚对局灶性脑缺血再灌注小鼠脑组织p-CREB、BDNF和p-STAT3的影响[J]. 首都医科大学学报, 2018, 39(3): 360-365.
[12]	徐世明, 王宏娟, 李中秋, 古同男, 许子华, 盛树力. 出生后营养干预对宫内发育迟缓大鼠学习记忆的影响[J]. 首都医科大学学报, 2017, 38(6): 851-856.
[13]	吕卫华, 王青, 赵清华, 吴薇, 翟雪靓, 张少景, 符琳琳. 住院老年病人营养状况与衰弱相关性研究[J]. 首都医科大学学报, 2017, 38(3): 377-380.
[14]	赵春松, 邹海强, 李晓波, 闫晓明, 关云谦, 张愚. CM-DiI标记人骨髓间充质干细胞并检测其移植后产生脑源性神经营养因子的实验研究[J]. 首都医科大学学报, 2017, 38(3): 423-430.
[15]	方伯梁, 钱素云. PICU脓毒症及严重脓毒症患儿肠内营养摄入能量及蛋白质充分性及其与预后的关系[J]. 首都医科大学学报, 2016, 37(2): 125-129.